GlassScriptPhysician profile
Muhammad A Ahmed
NPI 1275525933
$5,853.62
in general payments reported to CMS, 2019-2025
45 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $437 · 2021: $276 · 2022: $553 · 2023: $2,614 · 2024: $784 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,098 · Food and Beverage: $1,916 · Education: $45.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,098.48 |
| Food and Beverage | $1,915.56 |
| Education | $45.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,173.23 | 2023 | Da Vinci Surgical System |
| Insmed, INC. | $384.58 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $308.40 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $298.61 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.86 | 2019-2025 | Spiriva Respimat, Stiolto Respimat |
| Abbott Laboratories | $201.77 | 2019-2025 | Amplatzer Amulet |
| Regeneron Healthcare Solutions, INC. | $193.05 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $158.24 | 2020-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $148.79 | 2019-2024 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $145.14 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $143.02 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Abbvie INC. | $112.95 | 2021-2023 | Avycaz |
| Electromed, INC. | $94.99 | 2021-2023 | Smartvest |
| La Jolla Pharmaceutical Company | $93.19 | 2021-2025 | Giapreza |
| Genzyme Corporation | $81.46 | 2022-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.